Robert Goeltz II - Jan 23, 2024 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role: Chief Financial Officer
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Stock symbol: RCUS
Transactions as of: Jan 23, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/25/2024, 07:40 PM
Previous filing: Jan 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCUS	Common Stock	Award	$0	+21.3K	+41.1%	$0.00	73.1K	Jan 23, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCUS	Stock Option (right to buy)	Award	$0	+86.6K		$0.00	86.6K	Jan 23, 2024	Common Stock	86.6K	$15.44	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company.
F2	The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.